// Company Overview //
| Stock Name | 康哲藥業控股有限公司 |
| Stock Code | 00867 |
| Company Full Name | 康哲藥業控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事營銷、推廣及銷售國內外專業制藥公司的處方藥品,另亦生產及銷售多個處方藥。 |
| Listing Date | 2010-09-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港北角英皇道510號港運大廈21樓2106室 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.cms.net.cn |
| Share Registrar | 香港中央證券登記有限公司 |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2010-09-15 |
| Offer Price | HK$ 5.06 / shares |
| Total Funds Raised | HK$ 404,800,000 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
// First Day Performance
| First Day Close | Loading... |
| First Day Open | HK$ 5.85 |
| First Day Change | 11.46% |
| First Day Volume | 211863000.0 |
| First Day Turnover | 1255170000.0 |
// Price Chart //
// Use of Proceeds
| Use of Proceeds | 1、約8.3%或67.5百萬港元,將用于通過聘請更多合資格及專業員工及擴大醫院覆蓋范圍和地域范圍;
2、約12.5%或101.7百萬港元,將用于興建新培訓及會議中心以供進行醫生培訓、醫學會議及其他推廣活動以及員工培訓;
3、約8.3%或67.5百萬港元,將用于更換、改善或升級信息管理系統的軟硬件;
4、約33.3%或270.9百萬港元,將用于收購在中國推廣銷售藥品的獨家授權及尋求并購合適制藥公司的機會。
5、在取得理想的CMS024臨床進展后,約16.8%或136.7百萬港元,將用于興建一個生產廠房以供制造公司自行生產的藥品。
6、約10%或87.8百萬港元,將用于撥款向供應商采購進口藥品以滿足中國市場對我們的授權引進產品日益增加的需求;
7、約10%或81.3百萬港元,將用作我們的營運資金及其他一般企業用途; |
// Underwriting Syndicate //
// Cornerstone Investors //
This stock has no cornerstone investors.
// Directors & Management //
| Chairman | 林剛 |
| Company Secretary | 吳三燕 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 林剛(46.39%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.